D.E. Shaw & Co’s UroGen Pharma URGN Stock Holding History

D.E. Shaw & Co’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.4M	Buy	1,023,159 +60,535	+6%	+$1.21M	0.01%	1209
2025 Q4	$22.5M	Buy	962,624 +73,691	+8%	+$1.6M	0.01%	1173
2025 Q3	$17.7M	Buy	888,933 +861,501	+3,140%	+$15.5M	0.01%	1262
2025 Q2	$376K	Buy	+27,432	New	+$263K	﹤0.01%	3764
2024 Q3	–	Sell	-10,843	Closed	-$182K	–	4911
2024 Q2	$182K	Buy	+10,843	New	+$154K	﹤0.01%	4092
2024 Q1	–	Sell	-77,873	Closed	-$1.17M	–	4762
2023 Q4	$1.17M	Buy	77,873 +44,240	+132%	+$574K	﹤0.01%	3039
2023 Q3	$471K	Buy	+33,633	New	+$540K	﹤0.01%	3449

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co's URGN Position: Q1 2026 in Review

D.E. Shaw & Co increased its UroGen Pharma (URGN) stake by 6.3% in Q1 2026, buying an estimated $1.21M and bringing the position to 1,023,159 shares worth $18.4M. The position accounts for 0.01% of the portfolio, ranked #1209.

D.E. Shaw & Co first reported a position in URGN in Q3 2023 and has held it in 7 quarters since. The position peaked at $22.5M in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

D.E. Shaw & Co held 1,023,159 shares of UroGen Pharma worth $18.4M as of Q1 2026.
D.E. Shaw & Co bought 60,535 UroGen Pharma shares in Q1 2026, an estimated $1.21M.
UroGen Pharma made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1209 holding.
D.E. Shaw & Co first reported a position in UroGen Pharma in Q3 2023 and has held it in 7 quarters since.
D.E. Shaw & Co's UroGen Pharma position peaked at $22.5M in Q4 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.